Overview
Share price change
24h
Current
Min
144.71
Max
151.36
Income | -6.1M -22M |
|---|---|
Employees | 29 |
EBITDA | -5.8M -20M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +58.57% upside |
Next Earnings | 5 Nov 2026 |
|---|
Market Cap | -129M 1.6B |
|---|---|
Previous open | 151.09 |
Previous close | 145.22 |
Palvella Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
30 Oct 2026, 23:51 UTC
FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.
Read
30 Oct 2026, 23:51 UTC
BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.
Read
30 Oct 2026, 23:51 UTC
Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.
Read
30 Oct 2026, 23:41 UTC
Allegro Microsystems Inc. reported Q2 FY27 sales of $276.88M, exceeding expectations, and provided Q3 guidance of $278M to $288M, with shares modestly higher in after-market trading.
Read
30 Oct 2026, 23:41 UTC
BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in the stock's price during after-market hours.
Read
30 Oct 2026, 23:36 UTC
Capri Holdings Ltd reported Q2 profit of 42 cents per share and raised full-year EPS forecast to $2.20, with shares trading lower in after-market hours.
Read
30 Oct 2026, 23:31 UTC
McGrath RentCorp will replace Glaukos in the S&P 600 index at the market open on November 4, 2026, contributing to positive after-market price movement.
Read
30 Oct 2026, 23:26 UTC
JP Morgan maintains its Underweight rating on T. Rowe Price while raising the price target to $107; TD Cowen lowers its target to $96.
Read
30 Oct 2026, 23:26 UTC
Citigroup reaffirms Buy rating on Fortrea Holdings Inc and raises price target to $27, according to a report published today.
Read
30 Oct 2026, 23:21 UTC
Compass Inc. faces a class action lawsuit from Pomerantz LLP, alleging securities fraud related to its merger with Anywhere Real Estate Inc.
Read
30 Oct 2026, 23:16 UTC
JP Morgan maintains Neutral rating on Dexcom Inc and raises its price target to $85, reflecting the company's market position and growth potential.
Read
30 Oct 2026, 23:11 UTC
Pomerantz LLP has filed a class action lawsuit against The Chemours Company, alleging misleading statements and violations of federal securities laws.
Read
30 Oct 2026, 23:11 UTC
Cantor Fitzgerald identifies Binance's $6.3 billion hack as a potential buying opportunity for crypto-linked stocks, including Strategy Inc., amid recovery confidence.
Read
30 Oct 2026, 23:06 UTC
Uranium Energy Corp. shares declined in after-market hours, reflecting broader sector pressures despite analysts noting tightening supply in the uranium market.
Read
30 Oct 2026, 23:06 UTC
S&P Global Ratings revised its outlook on Meta Platforms, Inc. to negative, citing uncertainty over capital expenditures and projected free operating cash flow deficits.
Read
30 Oct 2026, 23:06 UTC
eBay expands managed shipping program amid seller eligibility concerns.
Read
30 Oct 2026, 23:06 UTC
Coinbase Global, Inc. received an Overweight rating from JP Morgan, which lowered its price target to $187 amid security concerns following the $6.3 billion Binance hack.
Read
30 Oct 2026, 23:06 UTC
Starbucks plans to trial an AI-driven "fast pass" feature for drive-throughs to enhance customer experience, leveraging its app and loyalty program.
Read
30 Oct 2026, 23:06 UTC
Kraft Heinz Company shares are trading modestly higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.
Read
30 Oct 2026, 23:06 UTC
The Hershey Company is trading higher in after-market hours, following analysts' adjustments with Evercore ISI lowering its price target to $200 and TD Cowen maintaining $198.
Read
30 Oct 2026, 23:06 UTC
DraftKings Inc. shares declined in after-market trading, pulling back from earlier gains as investors anticipate an upcoming earnings report amid ongoing pressure.
Read
30 Oct 2026, 23:06 UTC
Celsius Holdings faces a class action lawsuit from Pomerantz LLP over alleged federal securities law violations related to its Alani Nu energy drinks' marketing practices.
Read
30 Oct 2026, 23:06 UTC
Citigroup maintains a Neutral rating on Enphase Energy and lowers its price target to $25, which may have influenced investor sentiment.
Read
30 Oct 2026, 23:06 UTC
Ares Capital Corp announces a merger agreement to acquire MidCap Financial Investment Corporation, leading to the cancellation of MidCap's earnings call on November 5, 2026.
Read
30 Oct 2026, 23:02 UTC
Bitcoin has declined below $77K following a significant security breach at Binance, resulting in the theft of approximately $6.3 billion and raising cybersecurity concerns.
Read
30 Oct 2026, 23:01 UTC
Dyadic International Inc will report its Q3 2026 financial results and host a conference call on November 12, 2026, to enhance investor transparency.
Read
30 Oct 2026, 23:01 UTC
Rivian Automotive reported Q3 revenue of $2.15 billion and raised full-year delivery guidance to 67k units, despite shares falling in after-market trading.
Read
30 Oct 2026, 23:01 UTC
BWX Technologies Inc. is rising in after-market trading after being selected by the U.S. Army for a $2.2 billion nuclear microreactor project.
Read
30 Oct 2026, 23:01 UTC
JP Morgan maintains Neutral rating on Republic Services and raises price target to $265, following an update published after the market close.
Read
30 Oct 2026, 23:01 UTC
Twilio Inc. is under investigation by Levi & Korsinsky for potential federal securities law violations related to its lowered Q4 revenue growth guidance.
Read
Peer Comparison
Price change
Palvella Therapeutics Inc Forecast
Price Target
By TipRanks
12 Months Forecast
Average 231.75 USD 58.57%
High 267 USD
Low 207 USD
Based on 13 Wall Street analysts offering 12 month price targets forPalvella Therapeutics Inc - Dist in the last 3 months.
Rating Consensus
By TipRanks
Strong Buy
13 ratings
13
Buy
0
Hold
0
Sell
Based on 13 analysts giving stock ratings to Palvella Therapeutics Inc - Dist in the past 3 months.
Financials
Selling and administration expenses
Pre-tax profit
Sales
Interest expense on debt
EBITDA
Operating profit
$